Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
Nat Rev Drug Discov
| Authors | |
| Abstract | A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials. |
| Year of Publication | 2016
|
| Journal | Nat Rev Drug Discov
|
| Volume | 15
|
| Issue | 9
|
| Pages | 589-90
|
| Date Published | 2016 Sep
|
| ISSN | 1474-1784
|
| DOI | 10.1038/nrd.2016.155
|
| PubMed ID | 27469032
|
| Links |
